control groups – Page 6 – Communicable Diseases Research

Analysis of serum cytokine and protective vitamin D levels in severe cases of COVID-19

Article

Published on 2022-01-012022-11-16
Journal: Journal of medical virology [Category] Fulltext, MERS, 치료기술,

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

영국에서 2 가지 용량의 Chadox1 NCOV-19 또는 BNT162B2에 따른 3 가지 용량 (부스터)으로서 7 개의 코비드 -19 백신의 안전성 및 면역 원성

Clinical Trial

Published on 2021-12-182022-08-13
Journal: Lancet (London, England) [Category] Fulltext, SARS, 임상,

[키워드] 95% CI Ad26 Ad26.COV2.S adverse event age anti-Spike IgG antibody assigned blinded BNT BNT162b2 booster booster vaccination booster vaccines cellular response Cellular responses ChAd ChAdOx1 ChAdOx1 nCoV-19 Control control group control groups Course COV-BOOST COVID-19 COVID-19 vaccine CureVac CVn CVnCoV dose eligibility criteria ELISA female finding FIVE funding generate geometric mean geometric mean ratio geometric mean ratios GMR GMRs group humoral Humoral and cellular responses immunogenicity individuals initial intention-to-treat population investigated IQR ISRCTN janssen laboratory-confirmed SARS-CoV-2 infection Local m1273 median age MenACWY meningococcal conjugate vaccine Moderna modified intention-to-treat mRNA1273 multicentre neutralising response neutralising responses Novavax NVX NVX-CoV2373 Older Older age outcome Pain participant Participants Pfizer Phase 2 phase 2 trial primary analysis quadrivalent meningococcal conjugate vaccine randomised Randomly ranged reactogenicity referred to Registered Safety SARS-COV-2 infection screened secondary Secondary outcomes Serious Adverse Events Seven spike IgG systemic adverse events the median three group three groups treat treatment allocation Trial Vaccine vaccine availability Valneva Viral viral neutralisation VLA2001 were assessed were blinded white wild-type
[DOI] 10.1016/S0140-6736(21)02717-3 PMC 바로가기 [Article Type] Clinical Trial

An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection

비강내 OMV 기반 백신은 SARS-CoV-2 감염에 대한 높은 점막 및 전신 보호 면역을 유도합니다

Immunology

Published on 2021-12-172022-09-11
Journal: Frontiers in Immunology [Category] SARS, 변종, 진단, 치료기술, 치료제,

[키워드] administer Administered administration Against antibody booster vaccination booster vaccinations candidate vaccine CHO cells clinical development clinical testing control group control groups COVID-19 COVID-19 vaccine COVID-19 vaccines Cramp D614G effective eight greater hamster hamsters Histopathology IgA IgG IgG response immune protection immune response Immunity Immunoglobulin Immunoglobulin G inactivated induce intramuscular intramuscular vaccination intramuscularly intranasal intranasally lesion Local lung Lungs majority membrane vesicles mice mRNA mucosal mucosal immunity Neisseria Neisseria meningitidis Neutralizing antibodies nose offer OMV outer membrane outer membrane vesicle pandemic peptide peptide sequence practicality produced proline Protecting reduced Registered required SARS-CoV-2 SARS-CoV-2 pandemic second vaccination sequence serum Spike protein subunit Subunit vaccine Support systemic the SARS-CoV-2 Transmission vaccination Vaccinations Vaccine variants Vesicle Viral viral entry viral replication Viral vector weight loss
[DOI] 10.3389/fimmu.2021.781280 PMC 바로가기 [Article Type] Immunology

An eHealth Intervention for Promoting COVID-19 Knowledge and Protective Behaviors and Reducing Pandemic Distress Among Sexual and Gender Minorities: Protocol for a Randomized Controlled Trial (#SafeHandsSafeHearts)

Protocol

Published on 2021-12-102022-10-29
Journal: JMIR Research Protocols [Category] COVID-19,

[키워드] Anxiety Behavior Canada Care center conducted Control control groups Controlled COVID-19 COVID-19 knowledge COVID-19 pandemic Depression effective Effectiveness Efficacy eHealth evaluate Evidence exit expected Gender Generalized Health HIV Identifier identity include India individual Intervention intervention effect lack LGBT LGBT+ loneliness Measures media men mental health Mumbai n=36 objective Older organizations outcome participant Population populations prevention Primary outcome Promoting Protective Protective behaviors Psychological distress Randomized controlled trial RCT recruited recruitment reduce Registration report Result risk SARS-COV-2 infection secondary selected severe disease Sex sexual social determinant stratified Stress subgroup subgroups Tablet Thailand Toronto Trial US CDC women World Health Organization
[DOI] 10.2196/34381 PMC 바로가기 [Article Type] Protocol

COVID-19 in renal transplant recipients and general population: a comparative study of clinical, laboratory, and radiological features, severity, and outcome

신장 이식 수용자 및 일반 인구의 COVID-19 : 임상, 실험실 및 방사선 특징, 심각도 및 결과에 대한 비교 연구

Comparative Study

Published on 2021-12-072022-09-01
Journal: Virology Journal [Category] SARS, 진단,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Admission adverse outcome adverse outcomes ALC caused clinical clinical outcomes clinical symptom Clinical symptoms Computed tomography control group control groups coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 creatinine death disease disease severity Dyspnea enrolled exclusion criteria feature General population High-resolution Hospital stay HRCT hypertension ICU ICU admission Immunosuppressed Immunosuppression intensive care intensive care unit kidney transplant recipients Kidney transplantation Laboratory lung involvement mechanical ventilation Mortality mortality rate no significant difference not significantly different outcome Patient Platelet Platelet count pleural effusion prevalent radiological features recipient renal respiratory Result risk SARS-CoV-2 severe acute respiratory syndrome Coronavirus severity significant difference significantly higher significantly more Symptoms Transplant recipients two groups with COVID-19
[DOI] 10.1186/s12985-021-01713-x PMC 바로가기 [Article Type] Comparative Study

Real World Long-term Assessment of The Efficacy of Tocilizumab in Patients with COVID-19: Results From A Large De-identified Multicenter Electronic Health Record Dataset in the United States

COVID-19 환자에 대한 토실리주맙의 효능에 대한 실제 장기 평가: 미국에서 익명화된 대규모 다기관 전자 건강 기록 데이터 세트의 결과

Multicenter Study

Published on 2021-12-012022-09-12
Journal: International Journal of Infectious Diseases [Category] SARS, 진단,

Is COVID-19 associated with latent toxoplasmosis?

COVID-19는 잠재적인 톡소플라스마증과 관련이 있습니까?

Article

Published on 2021-12-012022-09-11
Journal: Environmental science and pollution research inter [Category] MERS, SARS, 진단, 치료기술,

A Systematic Review of the Protective Effect of Prior SARS-CoV-2 Infection on Repeat Infection

반복 감염에 대한 이전 SARS-CoV-2 감염의 보호 효과에 대한 체계적인 검토

Article

Published on 2021-12-012022-09-11
Journal: Evaluation & the health professions [Category] SARS, 변종,

[키워드] Analysis average risk baseline Case report Case series Chain Reaction Cohort Cohort studies cohorts conducted control groups COVID COVID-19 criteria determined by Effect eligible estimate excluded Follow-up human participants identify Immunity individuals infected with SARS-CoV-2 Infection information medRxiv natural immunity outcome participant PCR polymerase chain polymerase chain reaction Prior infection protection protective effect Re-infection reduction Reinfection Repeat Research retrieved review risk SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variants searched Standard deviation systematic analysis systematic review uninfected vaccination Vaccine was used were excluded
[DOI] 10.1177/01632787211047932 PMC 바로가기 [Article Type] Article

Pet Ownership and Multiple Sclerosis during COVID-19

Article

Published on 2021-12-012022-10-29
Journal: International Journal of Environmental Research an [Category] Coronavirus, SARS,

Impact of respiratory infectious epidemics on STEMI incidence and care

Article

Published on 2021-11-292022-10-29
Journal: Scientific Reports [Category] COVID-19, MERS,